Belara® - Proven benefits in daily practice

European Journal of Contraception and Reproductive Health Care

Volumn 10, Issue SUPPL. 1, 2005, Pages 19-25

  Bitzer, J ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Antiandrogenic activity; Daily practice; Ethinylestradiol chlormadinone acetate; Oral contraceptive; Patient profiles

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; GLUCOCORTICOID; LEVONORGESTREL; MINERALOCORTICOID; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ACNE; ANAMNESIS; BLOATING; BODY MASS; CLINICAL TRIAL; CONFERENCE PAPER; CONTRACEPTION; COUNSELING; DEMOGRAPHY; DRUG ACTIVITY; DRUG CHOICE; DRUG MARKETING; DRUG SAFETY; DYSMENORRHEA; EUROPE; EXPECTATION; FAMILY PLANNING; HEALTH; HORMONE ACTION; HUMAN; LIBIDO DISORDER; LIFE; LIVER METABOLISM; MENSTRUAL IRREGULARITY; MENTAL HEALTH; PARAMETER; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RISK FACTOR; SEBORRHEA; SEXUAL BEHAVIOR; SIDE EFFECT; STATISTICAL ANALYSIS; THERAPEUTIC ERROR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; FEMALE; QUALITY OF LIFE;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; CHLORMADINONE ACETATE; ETHINYL ESTRADIOL; FEMALE; HUMANS; QUALITY OF LIFE;

EID: 29044435770     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180500434962     Document Type: Conference Paper

References (9)

1. Curran MP, Wagstaff AJ. Ethinylestradiol/Chlormadinone acetate. Drugs 2004;64:751-60.
2. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63: 463-92.
3. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®). Dermatology 2001;203:38-44.
4. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®): results of a postmarketing surveillance study. Ciln Drug Invest 2002;22:221-31.
5. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception 2003;67:305-12.
6. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new anti-androgenic oral contraceptive Belara®. Contraception 1998;57:103-9.
7. Bitzer J. Contraception from the women's point of view (Part 1). Praxis 2000;89:1142-6.
8. Bitzer J. Contraception from the women's point of view (Part 2): Longterm pill users are convinced of the advantages of hormonal contraception. Praxis 2000;89: 1237-42.
9. Bitzer J, Hänggi W, Husslein P, et al. Longterm contraception. Recommendations of an Austrian-Swiss-Working Group. Gynäkologisch- geburtshilfliche Rundschau 2002;41:253-9.